small molecule

GIAPREZA

ANGIOTENSIN II ACETATE

Loss of exclusivityJanuary 2037latest FDA-listed patent expiry
CompanyLA JOLLA PHARMA LLC

Drug detail

Brand nameGIAPREZA
Active ingredientANGIOTENSIN II ACETATE
StrengthEQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusRX

Listed patents

PatentExpiresType
11219662January 2037use U-3262
10028995December 2034use U-2338
9220745December 2034use U-2217
10493124December 2034use U-2679
11559559December 2034use U-3514
11096983December 2034use U-3212
9572856July 2031use U-2221
9867863December 2029use U-2231
10500247December 2029use U-2680
10335451December 2029use U-2581
10548943December 2029use U-2739

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GIAPREZA patent cliff — loss of exclusivity January 2037 | CliffBio